A5073709637- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Hematopoietic Stem Cell Transplantation
- Virus-based gene therapy research
- Platelet Disorders and Treatments
- Viral Infectious Diseases and Gene Expression in Insects
- Advancements in Semiconductor Devices and Circuit Design
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Immune Cell Function and Interaction
- Mesenchymal stem cell research
- Kruppel-like factors research
- Organ Transplantation Techniques and Outcomes
- Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Protein Degradation and Inhibitors
- Integrated Circuits and Semiconductor Failure Analysis
- Cancer, Hypoxia, and Metabolism
- Cell Adhesion Molecules Research
- Acute Myeloid Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Cancer-related molecular mechanisms research
- Nanowire Synthesis and Applications
- Liver physiology and pathology
Xuzhou Medical College
2016-2025
Affiliated Hospital of Xuzhou Medical College
2011-2025
Dalian Maritime University
2025
Janssen (United States)
2021-2023
Cell Technology (China)
2020
King's College Hospital NHS Foundation Trust
2012
King's College London
2012
Osaka Hospital
2011
G protein-coupled receptor, class C group 5 member D (GPRC5D) is considered to be a promising surface target for multiple myeloma (MM) immunotherapy. Here, we report the efficacy and safety of anti-GPRC5D chimeric antigen receptor (CAR) T cells in patients with relapsed or refractory (R/R) MM.This phase Ⅱ, single-arm study enrolled (18-70 years) R/R MM. Lymphodepletion was performed before received 2 × 106/kg CAR cells. The primary end point proportion who achieved an overall response....
Despite the high therapeutic response achieved with B-cell maturation antigen (BCMA)-specific chimeric receptor (CAR) T-cell therapy in relapsed and refractory multiple myeloma (R/R MM), primary resistance relapse exist single-target immunotherapy. Here, we design bispecific BC19 CAR T cells targeting BCMA/CD19 evaluate antimyeloma activity vitro vivo. Preclinical results indicate that specifically recognize target antigens, mediate selective killing of BCMA or CD19-positive cancer cells....
Chimeric antigen receptor T (CAR-T) cell therapy has shown promising results for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). The immune response induced by murine single-chain variable fragment (scFv) of the CAR may limit CAR-T persistence and thus increases risk relapse. In this study, we developed a novel humanized scFv from FMC63 antibody. A total 18 R/R ALL patients with or without prior CD19 were treated CD19-targeted cells (hCART19s). After lymphodepletion...
In addition to their hemostatic function, platelets play an important role in regulating the inflammatory response. The platelet NLRP3 inflammasome not only promotes interleukin-1β secretion, but was also found be upregulated during activation and thrombus formation vitro. However, of function vivo remains unclear. this study, we aimed investigate integrin αIIbβ3 signaling transduction. Using NLRP3−/− mice, showed that NLRP3-deficient do have significant differences expression...
Abstract Systematic and dynamic humoral immune reconstitution is little-known for patients with relapsed/refractory (R/R) multiple myeloma (MM) who received anti–B-cell maturation antigen (BCMA) chimeric receptor (CAR) T-cell therapy. We investigated the kinetics of B-cell, normal plasma cell, immunoglobulin recovery in 40 achieved ongoing response after anti-BCMA CAR All developed B-cell aplasia median duration was 70 days (range, 23-270). The count reached its nadir on day 7 returned to...
Although chimeric antigen receptor (CAR)-modified T cells have shown great success in the treatment of B cell malignancies, this approach has limited efficacy patients with solid tumors. Various modifications CAR structure been explored to improve efficacy, including incorporation two costimulatory domains. Because signals are transduced together during activation, we engineered a type CAR-T signal that was activated independently from tumor recapitulate physiological stimulation. We...
Chimeric antigen receptor (CAR)-T cell therapy, a new immunotherapy for relapsed and refractory (R/R) hematologic malignancies, can be accompanied by adverse events, including coagulation disorders. Here, we performed comprehensive analysis of parameters in 100 patients with R/R malignancies after receiving CAR-T therapy to illuminate the profiles disorders facilitate management A high incidence was observed, elevated D-dimer (50/100, 50%), increased fibrinogen degradation product (45/100,...
Abstract Background Chronic graft-versus-host disease (cGVHD) is an immune-related disorder that the most common complication post-allogenic hematopoietic stem cell transplant. Corticosteroids with or without calcineurin inhibitors (CNIs) remain mainstay of cGVHD treatment for first-line therapy. However, many patients, symptoms cannot be effectively managed and thus require second-line Currently, there no approved in China. In this study, belumosudil, a highly selective potent...
Abstract Relapsed/refractory multiple myeloma patients with extramedullary disease (EMD) have unfavorable prognosis and lack effective therapy. Chimeric antigen receptor (CAR) T‐cell activities in EMD yet to be determined; how EMD‐specific microenvironment influences the clinical outcomes of CAR therapy remains great interest. In this prospective cohort study, histologically confirmed extra‐osseous were enrolled treated combined anti‐BCMA anti‐CD19 from May 2017 September 2023. Thirty‐one...
Chimeric antigen receptor T (CAR-T) cells are effective in treating hematological malignancies. However, patients receiving CAR-T therapy, data characterizing cardiac disorders limited.126 with hematologic malignancies cell therapy were analyzed to determine the impact of on occurrence disorders, including heart failure, arrhythmias, myocardial infarction, which defined by Common Terminology Criteria for Adverse Events (CTCAE). Parameters related detected enzyme, NT-proBNP and ejection...
Factors associated with outcomes of chimeric antigen receptor (CAR)-T cell therapy in patients relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) have not been fully elucidated. We explored the impact prelymphodepletion (pre-LD) lymphocyte to monocyte ratio (LMR) and its lactate dehydrogenase (LDH) (LMR/LDH) on efficacy prognosis 60 R/R DLBCL undergoing CAR-T therapy. The optimal cutoff values for pre-LD LMR LMR/LDH were 3.583 0.0103, respectively. overall response rate...
Background In recent years, chimeric antigen receptor (CAR)-T cell therapy has achieved tremendous efficacy in relapsed/refractory multiple myeloma (R/R MM). However, the impact of antibiotic (ATB) use on R/R MM patients treated with CAR-T is still not known. The aim our study was to analyse influence ATB clinical outcomes cells. Methods this retrospective study, 199 who received cells between January 2018 and December 2023 were evaluated from two hospitals China. They stratified into...
Abstract The aim of this study was to evaluate the role NLRP3 inflammasome on BU/CY-induced liver inflammation in mice after HSCT. HSCT model established through infusion 5 × 10 6 bone marrow mononuclear cells conditioned with BU/CY. On day 7, 14, 21 and 28 HSCT, were sacrificed for analysis inflammation, cytokine secretion, expression caspase-1 activation as well release ATP high-mobility group protein B1 (HMGB1). Furthermore, selective inhibitor (BAY 11-7082) administrated into its effects...
As a nonspecific alkylating antineoplastic agent, busulfan has been widely used in the treatment of patients with chronic myeloid leukemia. In vitro and vivo studies demonstrated busulfan-induced cell apoptosis. Whether triggers platelet apoptosis remains unclear. This study aimed to evaluate role Isolated human platelets were incubated followed by analysis flow cytometry or western blot, including mitochondrial depolarization, expression Bcl-2, Bax caspase 3 activation. Meanwhile,...
Platycodin D (PD) is one of the major bioactive components roots Platycodon grandiflorum and possesses multiple biological pharmacological properties, such as antiviral, anti-inflammatory, anti-cancer activities. However, whether it affects platelet function remains unclear. This study aims to evaluate role PD in thrombus formation. Platelets were treated with followed by measuring aggregation, activation, spreading, clot retraction, expression glycoprotein receptors. Moreover, mice...